$MANKIND Mankind Pharma announced its Q4 FY26 results today (20 May 2026),

Mankind Pharma announced its Q4 FY26 results today (20 May 2026), delivering strong growth across revenue and profit. Mankind Pharma Q4 FY26 Results Metric Q4 FY26 YoY Change Revenue from Operations ₹3,443 crore ▲ 11.8% Net Profit ₹559 crore ▲ 30.4% EBITDA ₹720 crore ▲ 18% EBITDA Margin 20.9% ↑ 120 bps EPS ₹14.2 vs ₹10.9 last year Business Highlights Domestic Formulations: Strong growth in anti-infectives, cardiovascular, and gastrointestinal segments. Consumer Healthcare: Brands like Prega News and Manforce contributed double-digit growth. Exports: Revenue up 9% YoY, driven by US and emerging markets. R&D: Increased investment in specialty and chronic therapies. Management Commentary Management highlighted robust demand in chronic therapies and consumer healthcare. Focus remains on expanding specialty portfolio and strengthening exports.